Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shortage Could Cause Early Access To Developmental Gaucher Disease Drugs

Executive Summary

Shire and Protalix BioTherapeutics' experimental Gaucher disease drugs could enter the market early to help offset likely treatment shortages created by manufacturing problems with the only enzyme replacement therapy currently approved for the orphan condition: Genzyme's Cerezyme

You may also be interested in...



Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme

Lower antibody formation could offer significant differentiation from Genzyme's product.

EMEA Inspection Findings Portend Further Manufacturing Problems For Genzyme

Market analysts note growing concerns about biotech's ability to handle manufacturing difficulties at Allston Landing, Mass., plant.

Multiple Factors Suggest Genzyme Still Faces Cerezyme Production Problems

In the weeks since Genzyme announced the shutdown of its Allston Landing, Mass., production facility because of viral contamination, the actual severity of the problem has been much debated. On Aug. 10, investors and industry watchers gleaned more about the true extent of the problem, with the Cambridge, Mass.-based big biotech's announcement it had discarded roughly 80 percent of the work-in-process material for Cerezyme (imiglucerase) that remained from when the Allston plant was closed for decontamination in mid-June

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS051270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel